A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD). Participants were ages 5 to 17 years with ASD and clinically significant anxiety (Pediatric Anxiety Rating Scale [PARS] score ≥10). Thirty participants were randomized to mirtazapine (7.5-45 mg/day) or placebo in a 2:1 ratio. The co-primary outcome measures were the PARS and the Clinical Global Impressions-Improvement subscale (CGI-I). Mirtazapine resulted in a statistically significant within group decrease in anxiety on the PARS (ES 1.76, p < 0.001). The improvement in PARS score for mirtazapine versus placebo was clinically meaningful but not statistically significant (ES = 0.63, p = 0.64). Forty-seven percent of participants assigned to mirtazapine (95% CI 22%: 74%) and 20% assigned to placebo (95% CI 2%: 60%) were rated "much improved" (CGI-I = 2) or "very much improved" (CGI-I = 1) for anxiety, p = 0.46. No statistically significant differences in mean 10-week changes between mirtazapine and placebo occurred on any outcome measure. There were no statistically significant differences in adverse effect frequency between mirtazapine and placebo. The results are consistent with mirtazapine's safety and tolerability and meet three of four pre-specified indicators of efficacy (statistically significant change in total PARS score for mirtazapine, numerically greater reduction in total PARS score for mirtazapine than placebo, numerically higher number of responders to mirtazapine than placebo, but not greater than 50% of participants receiving mirtazapine rated as responders). Implementation of a larger randomized controlled trial of mirtazapine for the treatment of anxiety in this population is supported.Clinical trial registration information: Mirtazapine Treatment of Anxiety in Children and Adolescents with Pervasive Developmental Disorders; https://clinicaltrials.gov ; NCT01302964.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A non-significant trend toward superiority of mirtazapine compared with placebo was observed with the PARS (effect size = 0.63).”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [102]
In the citing paper
“The study was a 10-week RCT comparing mirtazapine (mean dosage = 41.8 ± 5.2 mg/day) with placebo in youth with ASD ages 5–17 years [102].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [102]
In the citing paper
“To date, there has been only one published RCT of a medication, mirtazapine, for the treatment of anxiety in youth with ASD [102].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [102]
In the citing paper
“For 47% of participants assigned to mirtazapine, symptoms of anxiety were considered “much improved” (CGI-I = 2) or “very much improved” (CGI-I = 1) compared to 20% of those assigned to placebo.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [102]
In the citing paper
“It has shown good tolerability in an RCT for anxiety in youth with ASD [102].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [102]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065 · cited 2×
“Participants were diagnosed via clinical interview completed by a board-certified child and adolescent psychiatrist experienced in providing clinical care to youth with ASD, based on the DSM-IV diagnostic criteria, and corroborated by the Autism Diagnostic Interview-Revised (ADI-R) [22] administered by research reliab…”
MethodOwens, J. A., Spirito, A., & McGuinn, M. (2000) · Sleep · doi:10.1093/sleep/23.8.1d · Cited by 2,535 · cited 3×
“Secondary outcome measures included the SCARED [27], Child and Adolescent Symptom Inventory (CASI) Anxiety Items [28], ABC [29], Children’s Sleep Habit Questionnaire (CSHQ) [30], which was administered at baseline and weeks 2, 4, 6, and 10, and the CGI-S [26] and Developmental DisabilityChild Global Assessment Scale (…”
MethodInfluentialBIRMAHER, B., BRENT, D. A., CHIAPPETTA, L., BRIDGE, J., MONGA, S., & BAUGHER, M. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199910000-00011 · Cited by 2,252 · cited 3×
“Secondary outcome measures included the SCARED [27], Child and Adolescent Symptom Inventory (CASI) Anxiety Items [28], ABC [29], Children’s Sleep Habit Questionnaire (CSHQ) [30], which was administered at baseline and weeks 2, 4, 6, and 10, and the CGI-S [26] and Developmental DisabilityChild Global Assessment Scale (…”
MethodInfluentialAnxiety Disorders in Children and Adolescents with Autistic Spectrum Disorders: A Meta-Analysis
van Steensel, F. J. A., Bögels, S. M., & Perrin, S. (2011) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-011-0097-0 · Cited by 1,463
(1985) · PubMed · Cited by 1,427
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
A simple sample size formula for analysis of covariance in randomized clinical trials
Borm, G. F., Fransen, J., & Lemmens, W. A. J. G. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.02.006 · Cited by 575
Sukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Williams White, S., Lecavalier, L., et al. (2008) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-007-9165-9 · Cited by 518 · cited 2×
“Secondary outcome measures included the SCARED [27], Child and Adolescent Symptom Inventory (CASI) Anxiety Items [28], ABC [29], Children’s Sleep Habit Questionnaire (CSHQ) [30], which was administered at baseline and weeks 2, 4, 6, and 10, and the CGI-S [26] and Developmental DisabilityChild Global Assessment Scale (…”
MethodInfluentialSelf-citation(1996) · PubMed · Cited by 328
Research works printed but not linked: 3
- Anxiety Disorders Interview Schedule (ADIS-IV) Child/Parent Version Combination Specimen Set - Wendy K. Silverman; Anne Marie Albano - Oxford University Press. https://global.oup.com/academic/product/anxiety-disorders-interview-schedule-adis-iv-childparent-version-combination-specimen-set-9780195186741?cc=us&lang=en&. Accessed 23 June 2020.
- PPVT-4 Peabody Picture Vocabulary Test 4th Edition. https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Academic-Learning/Brief/Peabody-Picture-Vocabulary-Test-%7C-Fourth-Edition/p/100000501.html. Accessed 23 June 2020.
- Vineland Adaptive Behavior Scales – Second Edition (VinelandTM-II) - TSLAT. http://www.txautism.net/evaluations/vineland-adaptive-behavior-scales-second-edition-vinelandtm-ii. Accessed 23 June 2020.
Cited by
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Jiang, C.-C., Lin, L.-S., Long, S., Ke, X.-Y., Fukunaga, K., Lu, Y.-M., & Han, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01081-0 · Cited by 258
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-024-03814-0 · Cited by 51
“The study was a 10-week RCT comparing mirtazapine (mean dosage = 41.8 ± 5.2 mg/day) with placebo in youth with ASD ages 5–17 years [102].”
InfluentialSelf-citationSleep disturbances in autism spectrum disorder: Animal models, neural mechanisms, and therapeutics
Maurer, J. J., Choi, A., An, I., Sathi, N., & Chung, S. (2023) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2023.100095 · Cited by 33
Gupta, N., & Gupta, M. (2023) · Cureus · doi:10.7759/cureus.39446 · Cited by 31
“A second study of 20 adults with ASD found that mirtazapine reduced symptoms of anxiety, depression, and insomnia and improved social interactions [26].”
BackgroundBeversdorf, D. Q., Ferguson, B. J., Hunter, S., Hirst, K., Lolli, B., Bellesheim, K. R., Barton, A. U., Muckerman, J. E., Takahashi, N., Selders, K. J., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06452-1 · Cited by 29
“To our knowledge, there has only been one randomized controlled trial targeting anxiety in autism, demonstrating good tolerability but not significantly greater improvement in anxiety with mirtazapine as compared to placebo in this small study (McDougle et al. 2022).”
Metadata
- Authors
- McDougle, C. J., Thom, R. P., Ravichandran, C. T., Palumbo, M. L., Politte, L. C., Mullett, J. E., Keary, C. J., Erickson, C. A., Stigler, K. A., Mathieu-Frasier, L., & Posey, D. J.
- Affiliations
- Harvard University (US)
- University of North Carolina at Chapel Hill (US)
- Massachusetts General Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- Indiana University Indianapolis (US)
- Corresponding author
- McDougle, Christopher J.
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2022-03-03
- Volume
- 47
- Issue
- 6
- Pages
- 1263-1270
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC9019024
- OpenAlex
- W4214917350
- Cited by
- 31
- References
- 31
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 8 · 2023: 8 · 2022: 3
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Autism Speaks (#5717)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- mirtazapine, autism spectrum disorder, childhood anxiety, children and adolescents, selective serotonin reuptake inhibitors, adverse effects, drug safety and tolerability, treatment efficacy
- MeSH terms
- Autism Spectrum Disorder, Mirtazapine, Adolescent, Anxiety, Anxiety Disorders, Child, Child, Preschool, Double-Blind Method, Humans, Pilot Projects, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. https://app.cochat.ai/papers/10.1038/s41386-022-01295-4
- The paper
- McDougle, C. J., Thom, R. P., Ravichandran, C. T., Palumbo, M. L., Politte, L. C., Mullett, J. E., Keary, C. J., Erickson, C. A., Stigler, K. A., Mathieu-Frasier, L., & Posey, D. J. (2022). A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01295-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.